Search company, investor...
Histogenics company logo


Founded Year



Acq - P2P | Acquired

Total Raised


About Histogenics

Histogenics is a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop products for tissue repair and regeneration. Histogenics' flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement.

Headquarters Location

830 Winter Street 3rd Floor

Waltham, Massachusetts, 02451,

United States


Missing: Histogenics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Histogenics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Histogenics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Histogenics is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Histogenics Patents

Histogenics has filed 30 patents.

The 3 most popular patent topics include:

  • Orthopedic surgical procedures
  • Cell biology
  • Porous media
patents chart

Application Date

Grant Date


Related Topics




Prosthetics, Implants (medicine), Colloidal chemistry, Surfactants, Plastic surgery


Application Date


Grant Date



Related Topics

Prosthetics, Implants (medicine), Colloidal chemistry, Surfactants, Plastic surgery



Latest Histogenics News

Cartilage Repair Market Size Garner to Reach $2,195 Million by 2025 | CAGR of 15.0%

Oct 28, 2022

| CAGR of 15.0% News Provided By Share This Article Cartilage repair market report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics. PORTLAND, OREGON, UNITED STATES, October 27, 2022 / / -- Cartilage Repair Market by Modality, Type, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2018-2025, the global market was valued at $713 million in 2017, and is projected to reach $2,195 million by 2025, growing at a CAGR of 15.0% from 2018 to 2025. North America is anticipated to be the highest revenue contributor throughout the forecast period. ???????????????? ???????? ???????????? ???????????????????????????? : The report provides an extensive competitive analysis and profiles of the key market players such as Arthrex, Inc., B. Braun Melsungen AG, Conmed Corporation, Johnson & Johnson, Osiris Therapeutics, Inc., RTI Surgical, Inc., Smith & Nephew PLC, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc. The other players in the value chain (not included in the report) include Anika Therapeutics, Inc., Collagen Solutions LLP, and Histogenics Corporation. ???????????????????????????????? ???????????????????????? ???????????????????????? The cartilage repair market is anticipated to grow considerably in the near future, owing to different factors such as increase in obesity & sedentary lifestyle among the population, rise in elderly population, and upsurge in prevalence of arthritis globally. However, high costs associated with cartilage repair procedures and unclear regulatory scenario are the key factors that are expected to impede the market growth. On the contrary, the emerging markets such as India and China are anticipated to provide lucrative growth opportunities to the market players during the forecast period. By modality, chondroplasty & microfracture accounted for more than one-fourth share of the global cartilage repair market in 2017. In terms of application, the knee segment garnered nearly half of the market share in 2017, and is projected to exhibit prominent growth rate, owing to surge in prevalence of knee osteoarthritis globally. Among end users, hospitals & clinics generated the highest revenue in 2017, due to different factors such as availability of different treatment options (chondroplasty, osteochondral autograft transplantation, and others) under one roof, palliative care, and diagnosis. By region, North America was the highest revenue contributor in the global market in 2017. ???????????? ???????????????????????????????? ???????????????????????????? • Hyaline cartilage occupied nearly two-thirds share of in the cartilage repair market in 2017. • Knee application is anticipated to grow with the highest CAGR throughout the forecast period. • North America accounted for more than one-third share of the global cartilage repair market in 2017. • Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA. ???????????????????? ???????????????????????????????? ????????????????????????????: ????????????????????????- ???? ????????????????????????????????????????????????-???????????????????? ???????????????????????????? (???????????????????????????? ????????-????????????????????????, ????????????????????????????????????????????????-???????????????????? ???????????????????????????? ????????????????????) ???????????????????????????? ???????? ???????????????????????? ???????????????????????? ????????????????????????????????: AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. ???????????? ???????? ???????????????????????? ???????? ???????????? ???????????????????????????? ???????? ???????????????????????????? ???????? ???????????? ???????????????? ???????????????? ???????????? ???????????????????????? ???????????? ????????????????????????????????. ???????????? ???????????????? ????????????????????????????, ???????????????????????? ???????????? ????????????????: ???????????????????? ???????????????????????? ???????????????????????? ????????????????????????????????: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. David Correa

Histogenics Frequently Asked Questions (FAQ)

  • When was Histogenics founded?

    Histogenics was founded in 2000.

  • Where is Histogenics's headquarters?

    Histogenics's headquarters is located at 830 Winter Street, Waltham.

  • What is Histogenics's latest funding round?

    Histogenics's latest funding round is Acq - P2P.

  • How much did Histogenics raise?

    Histogenics raised a total of $81.42M.

  • Who are the investors of Histogenics?

    Investors of Histogenics include Ocugen, Split Rock Partners, Sofinnova Ventures, Boston Millennia Partners, Flare Capital Partners and 10 more.

  • Who are Histogenics's competitors?

    Competitors of Histogenics include Regentis Biomaterials, OcuNexus Therapeutics, Juventas Therapeutics, Arteriocyte, FirstString Research and 11 more.

Compare Histogenics to Competitors


Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

FirstString Research

FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.


Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.


CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.nCarticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel.


AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.